Database and Biobank of Patients With Hypersensitivity Pneumonitis

Condition(s) studied

Study summary

Sub-study of the main Pulmonary Fibrosis Biomarker (PFBIO) cohort (NCT02755441), recruiting patients with an MDT-diagnosis of hypersensitivity pneumonitis (HP). Patients are included for the collection of blood samples and regular clinical data.

The database and biobank will be available for studies of HP, and can be directly compared to the main PFBIO cohort, which has recruited patients with Idiopathic pulmonary Fibrosis (IPF) since 2016.

Biomarkers will be assessed as diagnostic and prognostic. Further subtyping of HP, based on blood markers (including precipitins) will also be possible with the PFBIO-HP project.

Eligibility

Primary outcome measure(s)

• Diagnosis of HP — 0 days
  MDT-Diagnosis of HP
• Exposure to inciting antigen (patient reported) — 0 days
  Known exposure, as reported by the patient
• Exposure to inciting antigen (measurable) — 0 days
  Measurable exposure, as tested by precipitins
• Progression free survival — 3 years
  Survival without progression
• Overall survival — 3 years
  Survival after diagnosis

Trial sites (1)

More Nils Hoyer trials in Denmark